EMVision Medical Devices Yönetim

Yönetim kriter kontrolleri 3/4

EMVision Medical Devices CEO'su Scott Kirkland, Jul2023 tarihinde atandı, in görev süresi 1.33 yıldır. in toplam yıllık tazminatı A$ 557.06K olup, şirket hissesi ve opsiyonları dahil olmak üzere 56.5% maaş ve 43.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 5% ine doğrudan sahiptir ve bu hisseler A$ 8.06M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 5.4 yıldır.

Anahtar bilgiler

Scott Kirkland

İcra Kurulu Başkanı

AU$557.1k

Toplam tazminat

CEO maaş yüzdesi	56.5%
CEO görev süresi	1.3yrs
CEO sahipliği	5.0%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

EMVision Medical Devices Ltd's (ASX:EMV) CEO Compensation Is Looking A Bit Stretched At The Moment

Nov 09

Recent updates

EMVision Medical Devices (ASX:EMV) Is Using Debt Safely

Aug 28

Is EMVision Medical Devices (ASX:EMV) A Risky Investment?

Nov 21

Here's Why We're Not At All Concerned With EMVision Medical Devices' (ASX:EMV) Cash Burn Situation

Apr 24

EMVision Medical Devices Ltd's (ASX:EMV) CEO Compensation Is Looking A Bit Stretched At The Moment

Nov 09

We're Not Very Worried About EMVision Medical Devices' (ASX:EMV) Cash Burn Rate

Oct 04

Companies Like EMvision Medical Devices (ASX:EMV) Are In A Position To Invest In Growth

Jun 17

Here's Why We're Not Too Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Situation

Feb 22

Investors Who Bought EMvision Medical Devices (ASX:EMV) Shares A Year Ago Are Now Up 319%

Dec 20

We Think EMvision Medical Devices (ASX:EMV) Can Afford To Drive Business Growth

Nov 24

CEO Tazminat Analizi

Scott Kirkland'un ücretlendirmesi EMVision Medical Devices'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$557k	AU$315k	-AU$3m
Mar 31 2024	n/a	n/a	-AU$3m
Dec 31 2023	n/a	n/a	-AU$3m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	AU$285k	AU$258k	-AU$4m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$5m
Sep 30 2022	n/a	n/a	-AU$5m
Jun 30 2022	AU$270k	AU$245k	-AU$6m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	n/a	n/a	-AU$7m
Sep 30 2021	n/a	n/a	-AU$8m
Jun 30 2021	AU$262k	AU$240k	-AU$8m
Mar 31 2021	n/a	n/a	-AU$7m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$4m
Jun 30 2020	AU$224k	AU$205k	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$3m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$213k	AU$150k	-AU$3m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	AU$45k	AU$41k	-AU$2m

Tazminat ve Piyasa: Scott 'ın toplam tazminatı ($USD 362.22K ) Australian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 298.55K ).

Tazminat ve Kazançlar: Scott şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Scott Kirkland

1.3yrs

Görev süresi

AU$557,063

Tazminat

Mr. Scott Kirkland has been an Executive Director of EMvision Medical Devices Limited since July 11, 2017 and serves as its Chief Executive Officer and Managing Director since July 01, 2023. Mr. Kirkland h...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Kirkland	CEO, MD & Executive Director	1.3yrs	AU$557.06k	5% A$ 8.1m
Emma Waldon	CFO & Company Secretary	7.3yrs	Veri yok	1.36% A$ 2.2m
Forough Khandan	Chief Technology Officer	1.8yrs	Veri yok	Veri yok
Stuart Crozier	Chairman of Clinical Advisory Board & Chief Scientific Officer	3.9yrs	Veri yok	1.22% A$ 2.0m
Robert Tiller	Head of Design	3.8yrs	Veri yok	Veri yok
Konstanty Bialkowski	Head of Tech Development	no data	Veri yok	Veri yok
Christian Wight	Head of Regulatory Affairs	1.6yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: EMV 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Scott Kirkland	CEO, MD & Executive Director	7.3yrs	AU$557.06k	5% A$ 8.1m
Stuart Crozier	Chairman of Clinical Advisory Board & Chief Scientific Officer	5.4yrs	Veri yok	1.22% A$ 2.0m
Geoffrey Donnan	Ex-Officio Member of Clinical Advisory Board	2.7yrs	Veri yok	Veri yok
Philip Dubois	Independent Non-Executive Director	4.2yrs	AU$55.50k	0.056% A$ 89.5k
John Keep	Non-Executive Chairman	6.7yrs	AU$105.45k	2.42% A$ 3.9m
Geoffrey Richard Pocock	Non-Executive Director	6.7yrs	AU$55.50k	1.0% A$ 1.6m
Tony Keane	Independent Non-Executive Director	6.4yrs	AU$51.83k	0.70% A$ 1.1m
Michael O'Sullivan	Member of Clinical Advisory Board	5.4yrs	Veri yok	Veri yok
David Cook	Member of Clinical Advisory Board	5.4yrs	Veri yok	Veri yok
James Walsham	Member of Clinical Advisory Board	5.4yrs	Veri yok	Veri yok
Ken Mitchell	Member of Clinical Advisory Board	5.4yrs	Veri yok	Veri yok
Stephen Davis	Ex-Officio Member of Clinical Advisory Board	2.7yrs	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: EMV 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).

EMVision Medical Devices Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

EMVision Medical Devices Ltd, Annual General Meeting, Nov 14, 2024

EMVision Medical Devices Ltd, Annual General Meeting, Nov 15, 2023

Less than half of directors are independent

EMVision Medical Devices Ltd's (ASX:EMV) CEO Compensation Is Looking A Bit Stretched At The Moment

EMVision Medical Devices Ltd, Annual General Meeting, Nov 16, 2022

Less than half of directors are independent

Recent updates

EMVision Medical Devices Ltd, Annual General Meeting, Nov 14, 2024

EMVision Medical Devices (ASX:EMV) Is Using Debt Safely

Full year 2024 earnings released: AU$0.034 loss per share (vs AU$0.05 loss in FY 2023)

EMVision Unveils Backpack-Sized Brain Scanner to Empower First Responders

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

EMVision Medical Devices Ltd has filed a Follow-on Equity Offering in the amount of AUD 15.281174 million.

EMVision Medical Devices Ltd has completed a Follow-on Equity Offering in the amount of AUD 15.281174 million.

EMVision Medical Devices Ltd announced that it expects to receive AUD 15.281174 million in funding from Keysight Technologies, Inc.

Is EMVision Medical Devices (ASX:EMV) A Risky Investment?

EMVision Medical Devices Ltd, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.05 loss per share (vs AU$0.081 loss in FY 2022)

New minor risk - Financial data availability

Emvision Medical Devices Limited Receives $1.75 Million Manufacturing Grant Award

Here's Why We're Not At All Concerned With EMVision Medical Devices' (ASX:EMV) Cash Burn Situation

No longer forecast to breakeven

EMVision Medical Devices Limited Provides an Update on Its Clinical Trial and Achievement of an Important Technical Development Milestone

EMVision Commences Clinical Trial

Less than half of directors are independent

EMVision Medical Devices Ltd Announces its Portable Brain Scanner Delivered to First Clinical Site

EMVision Medical Devices Ltd's (ASX:EMV) CEO Compensation Is Looking A Bit Stretched At The Moment

We're Not Very Worried About EMVision Medical Devices' (ASX:EMV) Cash Burn Rate

EMVision Medical Devices Ltd, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.081 loss per share (vs AU$0.12 loss in FY 2021)

Companies Like EMvision Medical Devices (ASX:EMV) Are In A Position To Invest In Growth

Less than half of directors are independent

EMvision Medical Devices Limited Announces Clinical Advisory Board Appointments

We're Not Very Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Rate

CEO, MD & Director exercised options to buy AU$2.3m worth of stock.

We're Not Very Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Rate

Full year 2021 earnings released: AU$0.12 loss per share (vs AU$0.057 loss in FY 2020)

EMvision Medical Devices Limited provides an update on the build of its First Gen device

We're Not Very Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Rate

Medical Devices Limited Announces Australian Stroke Alliance in Collaboration with EMVision Wins Stage 2 MRFF Bid

Here's Why We're Not Too Worried About EMvision Medical Devices' (ASX:EMV) Cash Burn Situation

New 90-day low: AU$2.70

EMvision Medical Devices Limited Announces FDA Provides De Novo Guidance

New 90-day low: AU$2.71

EMvision Medical Devices Limited Submits 513(G) Request for Information to the United States Food and Drug Administration

Investors Who Bought EMvision Medical Devices (ASX:EMV) Shares A Year Ago Are Now Up 319%

EMVision Medical Devices Limited Appoints Stuart Crozier as Chief Scientific Officer

We Think EMvision Medical Devices (ASX:EMV) Can Afford To Drive Business Growth

New 90-day high: AU$3.01

EMvision Medical Devices Limited Announces Board Changes

New 90-day high - AU$2.35

Full year earnings released - AU$0.056 loss per share

New 90-day high - AU$1.90

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi